Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

1

Breast Cancer Therapeutics in Asia-Pacific
Markets to 2020 - Novel HER-2 Positive Therapies
Provide Diversified Treatment Options

Published By GBI Research
Published May 2014
2
Description


GBI Research, the leading business intelligence
provider, has released its latest research
"Breast Cancer Therapeutics in Asia-Pacific
Markets to 2020 - Novel HER-2 Positive Therapies
Provide Diversified Treatment Options", which
provides in-depth analysis of breast cancer
market within the Asia-Pacific (APAC) covering
the four countries of Australia, China, India and
Japan. The report provides an estimation of
market size for 2013, along with market forecast
until 2020. It also covers disease epidemiology,
treatment algorithms, treatment patterns,
in-depth analysis of the pipeline, and deal
analysis. The breast cancer therapeutics market
in the four Asia-Pacific (APAC) countries of
India, Australia, China and Japan was worth 1.5
billion in 2013 and is expected to grow at a
Compound Annual Growth Rate (CAGR) of 7.6 to
2.5 billion by 2020. Japan had the largest
market in 2013 with a value of 872m, or a share
of 58, followed by China with 320m or 21, and
Australia with 234m or 16. India had the lowest
market share and value at 5 and 81m, but is
expected to witness the fastest growth over the
forecast period with a CAGR of 13.8, compared to
Australia at 7.8 and China and Japan both at
7.7.
3
Description

Scope The report analyzes treatment usage
patterns, market characterization, pipeline
analysis and key licensing and co-development
deals in the breast cancer therapeutics in the
four APAC markets of Australia, China, India and
Japan. The report includes - - Disease overview,
as well as treatment algorithms and treatment
usage patterns - Market size and forecast for the
APAC breast cancer market from 2013 to 2020 -
Major marketed products in the APAC region along
with a heat map of product performance - In-depth
pipeline analysis for global pipeline in breast
cancer drugs along with clinical trial failure
rate analysis - Key drivers and restraints that
have had and are expected to have a significant
impact upon the market - Key licensing and
co-development agreements that could have impact
on growth trends
4
Description

Reasons to buy The report will enhance your
decision-making capability by allowing you to -
- Align your product portfolio to the markets
with high growth potential - Develop market entry
and expansion strategies by identifying the
potential regions and therapeutic segments poised
for strong growth - Devise a more effectively
tailored country strategy through the
understanding of key drivers and barriers in the
breast cancer drugs market - Develop key
strategic initiatives based upon an understanding
of key focus areas and leading companies -
Accelerate and strengthen your market position by
identifying key companies for mergers,
acquisitions and strategic partnerships
5
Table of Contents

• 1 Table of Contents
• 1.1 List of Tables
• 1.2 List of Figures
• 2 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 -Introduction 
• 2.1  Breast Cancer  
• 3 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 - Marketed Products 3.1
  Carboplatin
• 4 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 - Pipeline Analysis
• 5 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 - Market Forecast to 2020

6
Table of Contents

• 6 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 - Deals and Strategic
  Consolidations
• 7 Breast Cancer Therapeutics in Asia-Pacific
  Markets to 2020 Appendix
• For inquiry, kindly contact at
  http//www.reportsandintelligence.com/purchase-enq
  uiry/132441
• To check table of contents of the research, Visit
  _at_ http//www.reportsandintelligence.com/breast-ca
  ncer-therapeutics-in-asia-pacific-to-2020-novel-he
  r-2-positive-therapies-provide-diversified-treatme
  nt-options-market/table-of-contents

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/breast-cance
r-therapeutics-in-asia-pacific-to-2020-novel-her-2
-positive-therapies-provide-diversified-treatment-
options-market
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States